GALAPAGOS news, videos and press releases - Page 2
For more news please use our advanced search feature.
GALAPAGOS - More news...
GALAPAGOS - More news...
- First key steps in pipeline rebuild and strong commercial progress in H1 2022
- Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
- Galapagos increases share capital through subscription right exercises
- Galapagos receives transparency notification from FMR LLC
- Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
- Galapagos demonstrates regulatory and commercial progress in Q1 2022
- Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
- Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
- Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
- Galapagos creates new subscription right plan
- Galapagos appoints Paul Stoffels as Chief Executive Officer
- JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
- Galapagos creates new subscription right plan
- Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
- Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
- Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
- Galapagos reports H1 financial results with refocused pipeline and operational progress
- Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
- Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
- SELECTION study on filgotinib in ulcerative colitis published in The Lancet
- Transparency notification received from The Capital Group
- Galapagos creates new subscription right plans
- Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
- Galapagos increases share capital through subscription right exercises
- GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
- Transparency notification received from The Capital Group
- Pipeline and capital for growth
- Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
- The Capital Group holds 10.03% of Galapagos shares
- Selvita completes acquisition of Fidelta from Galapagos
